

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 262 200 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
04.12.2002 Bulletin 2002/49

(51) Int Cl.7: **A61L 27/20**
// (A61L27/20, C08L5:08)

(21) Application number: **02077105.1**

(22) Date of filing: **01.06.1995**

(84) Designated Contracting States:
DE ES FR GB IT NL SE

(30) Priority: **07.06.1994 US 255252**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
95303739.7 / 0 686 395

(71) Applicants:
• **GENZYME CORPORATION**
Cambridge, Massachusetts 02139 (US)
• **The Trustees of Boston University**
Boston, MA 02215 (US)

(72) Inventors:
• **Burns, James W.**
Boston, Massachusetts 02110 (US)
• **Valeri, Cesare R.**
Marblehead, Massachusetts 01945 (US)

(74) Representative: **Froud, Clive et al**
Elkington and Fife
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR (GB)

Remarks:

This application was filed on 28.05.02 as a divisional
application to the application mentioned under INID
code 62.

(54) **Inhibition of platelet adherence and aggregation**

(57) A prosthetic device characterised in that it is coated with hyaluronic acid in an amount sufficient to inhibit the interaction of platelets with the said device is disclosed.

EP 1 262 200 A2

Description

[0001] The invention relates to the inhibition of platelet adherence and aggregation via the administration of hyaluronic acid.

[0002] When a blood vessel is damaged and the normal endothelial-cell barrier is disrupted, platelets are quickly recruited from the circulating blood to form an occlusive plug. This occurs through a series of interactions between the platelets and macromolecules in the subendothelial matrix (platelet adhesion) and among the platelets themselves (platelet aggregation). The initial process of adhesion, in contrast to aggregation, does not require metabolic activity. It leads, however, to the activation of platelets which in turn secrete a number of factors which stimulate the activation of plasma coagulation factors, resulting in the generation of a fibrin clot that reinforces the platelet aggregate. Under normal hemostatic condition the platelet aggregate and fibrin clot are degraded as healing of the injured area occurs.

[0003] Thrombosis is a pathological process in which a platelet aggregate and/or fibrin clot occlude a blood vessel. Venous thrombosis and pulmonary embolism are among the leading causes of morbidity and death in hospitalized patients. Studies with radioactively labeled fibrinogen reveal venous thrombi in the lower legs of about one fourth of all patients older than 50 years who have undergone routine inguinal herniorrhaphy, in more than one half of all prostatectomy or hip surgery patients, and in about one third of all patients with acute myocardial infarction. Predisposing factors include posttraumatic and postoperative immobility (particularly in middle-aged and elderly patients and after cardiovascular procedures), pregnancy, previous episodes of venous thrombosis, use of oral contraceptives, stroke, neoplasia, obesity, systemic lupus erythematosus, nephrotic syndrome, polycythemia vera, inflammatory bowel disease, homocystinuria, hyperhomocysteinemia, paroxysmal nocturnal hemoglobinuria, shock, and congestive heart failure.

[0004] Thrombosis that develops as a purely intravascular process may also be the primary factor in atherosclerosis. The formation of platelet aggregates on the surface of atheromatous plaques and subsequent organization of these white thrombi into fibrous occlusive intimal lesions is undoubtedly one mechanism by which atherosclerotic lesions progress to severe obstruction and total occlusion; coronary artery thrombosis leading to myocardial infarction almost always occurs at the site of an atheromatous plaque. Percutaneous transluminal coronary angioplasty (PTCA) has become an important procedure to re-establish blood flow to the heart through partially occluded blood vessels. Unfortunately approximately 30% to 40% of patients that have coronary angioplasty suffer restenosis of the treated vessel within 6 months of treatment; currently there is no reliable method of preventing vascular restenosis. A revascularization procedure such as bypass surgery or another PTCA procedure is thus often required.

[0005] Current therapies for the prevention and treatment of thrombus formation associated with various disease states and surgical procedures have focused primarily on the use of the anticoagulants heparin or warfarin. Most commonly, basic therapy usually involves immediate heparinization which may be followed by long-term administration of warfarin if there is a prolonged risk of thrombus reoccurrence.

[0006] Heparin prevents the release of serotonin and thromboxane A_2 from platelets. These vasoactive substances are suspected mediators of the intense pulmonary artery hypertension, acute right-side hemodynamic failure, and cardiogenic shock associated with pulmonary embolism. Heparins' rapid action in preventing thrombus propagation and in blocking platelet release is the rationale for its use. However, a frequent complication of heparinization is major bleeding (usually after 48 hours); such bleeding is especially hazardous if it occurs intracranially. The risk of bleeding is dose related and is higher in woman, in severely ill patients, in individuals who consume large amounts of alcohol, and in individuals who take heparin and aspirin concurrently. Although the action of heparin may be terminated by intravenous injection of protamine sulfate, the use of protamine has been linked to several post-surgical complications, including postoperative systemic hypotension, allergic reactions, catastrophic pulmonary vasoconstriction, acute pulmonary hypertension, complement activation, noncardiogenic pulmonary edema, decreased cardiac output, and thrombocytopenia/leukopenia. Since protamine, usually isolated from fish, can be recognized as a foreign protein by the human immune system, patients with prior protamine exposure (e.g., diabetic patients who have received protamine insulin) are at particular risk during subsequent exposures (Just Viera, *Amer. Surgeon* 50:151, 1984). Additionally, studies suggest that a non-immunological pathway via complement activation may be responsible for many of the acute reactions observed during protamine reversal of heparin anticoagulation.

[0007] Warfarin interferes with the γ -carboxylation of glutamic acid residues in the vitamin K-dependent synthesis of factors II, VII, IX, and X in liver mitochondria. The drug is completely absorbed and is predominantly protein-bound in the plasma, where its half-life is 42 hours. It is degraded in the liver and its metabolites, which are inactive, are excreted in the urine and stool. However, warfarin will not affect procoagulant proteins already formed in the liver and released into the circulation, and the half-life of some of these factors is longer than 24 hours, thus delaying the anticoagulant effects of this drug for several days. In addition, a number of drugs interact significantly with warfarin, and hereditary resistance to warfarin exists as an autosomal dominant trait in some families.

[0008] If heparinization is ineffective to stop progression of thrombus formation, or in the cases where occlusion is acute and life threatening, thrombolytic therapy is usually used. Three thrombolytic agents are currently used; uroki-

nase, which is harvested from human fetal kidney cells and cleaves plasminogen to plasmin; streptokinase, which is derived from streptococci and complexes with and activates plasminogen; and recombinant tissue plasminogen activator (rtPA). These agents may hasten thrombus dissolution, but they also lyse hemostatic fibrin and may cause hemorrhaging. Thus, concurrent use of these thrombolytic agents with heparin or warfarin is usually avoided. In addition, the nonrecombinant agents are pyrogens and potential allergens, especially streptokinase, which has been associated with anaphylaxis.

[0009] Although venous thrombosis during pregnancy is common, and pulmonary embolism is a leading cause of maternal mortality, anticoagulant therapy during pregnancy poses significant therapeutic problems. Warfarin crosses the placenta and affects the fetus, in addition to being associated with hemorrhagic complications. Embryopathy (nasal hypoplasia, altered bone growth, and stippled epiphyses) has been clearly attributed to coumarin derivatives; the critical period for exposure appears to be between the sixth week and the twelfth week of gestation. Far less common are such serious fetal central nervous system abnormalities as mental retardation, blindness, deafness, spasticity, and seizures. These defects appear to be unrelated to any critical period of exposure and may be associated with warfarin administration during the second and third trimesters. Various congenital ocular abnormalities have also been reported after warfarin therapy.

[0010] Heparin does not cross the placenta, and currently, adjusted-dose heparin is the preferred anticoagulant used during pregnancy complicated by venous thromboembolism. However, in one study, about one-eighth of the pregnancies treated with heparin ended in stillbirth, and one fifth of the mothers gave birth to premature infants, one third of whom died. Other problems associated with heparin administration during pregnancy include retained placenta, premature detachment of the placenta and minor hematomas.

[0011] We have discovered that hyaluronic acid is capable of interfering with the interaction of von Willebrand factor (vWF) with platelets and components of the subendothelial matrix to effectively inhibit platelet aggregation and adhesion. Accordingly, this discovery permits the use of hyaluronic acid for the inhibition of platelet adherence and aggregation in a number of disease states which are or can be pathological.

[0012] In one aspect, the invention features a method of treating a thrombotic condition in a mammal, preferably a human, by administering to the mammal a therapeutic composition containing hyaluronic acid in a dosage effective to inhibit the adherence and aggregation of platelets within the mammal's vascular system.

[0013] In one preferred embodiment of this aspect, the thrombotic condition is venous thrombosis, particularly venous thrombosis which can lead to the development of pulmonary emboli (e.g., iliofemoral thrombosis, mesenteric vein thrombosis and Budd-Chiari syndrome). The method is especially useful in treating venous thrombosis during pregnancy.

[0014] In another preferred embodiment of this aspect, the thrombotic condition is arterial thrombosis, particularly coronary artery thrombosis.

[0015] In a second aspect, the invention features a method of preventing the formation of a thrombus in a mammal at risk of developing thrombosis by administering to the mammal a therapeutic composition containing hyaluronic acid in a dosage effective to inhibit the adherence and aggregation of platelets.

[0016] In one preferred embodiment of this aspect, the mammal is at increased risk of developing a thrombus due to a medical condition which disrupts hemostasis, including heparin induced thrombocytopenia, coronary artery disease, atherosclerosis, pregnancy, stroke, neoplasia, obesity, systemic lupus erythematosus, nephrotic syndrome, polycythemia vera, inflammatory bowel disease, homocystinuria, hyperhomocysteinemia, paroxysmal nocturnal hemoglobinuria, shock, and congestive heart failure.

[0017] In another preferred embodiment of this aspect of the invention, the mammal is at increased risk of developing a thrombus due to a medical procedure, including cardiac surgery, cardiopulmonary bypass, catheterization, cardiac catheterization, percutaneous transluminal coronary angioplasty, atherectomy. Also included are procedures which involve the placement of either a synthetic or bioprosthetic prosthesis (e.g., a cardiovascular valve).

[0018] In both of these aspects of the invention, HA may be administered systemically or locally. The administration of HA may occur prior to, during, or after a medical procedure, or treatment with other agents (e.g., thrombolytic agents).

[0019] In still another aspect, the invention also features a method of inhibiting the adherence of platelets to the surface of a prosthetic device by coating the device with hyaluronic acid in an amount sufficient to inhibit the interaction of the platelets with the surface of the device prior to exposure of the device to the platelets.

[0020] The device can be made of any suitable biocompatible material, either totally or partially synthetic, that is commonly used in medical procedures. In preferred embodiments, the prosthetic device is a coronary valve, vascular graft, or a stent.

[0021] Also in preferred embodiments of the invention, the HA solution concentration for systemic administration in the blood to prevent platelet adhesion is in the range of 0.1% to 0.4% (weight percent) and is administered in an amount greater than approximately 5% of the total blood volume of the patient and less than 15%. The viscosity of the HA solution should be less than 1000 centipoise and greater than 20 centipoise. The molecular weight of the HA can be adjusted according to the desired viscosity for a specific HA concentration. Preferably the average molecular weight

of the HA is greater than 1×10^5 daltons; more preferably, between 2.25×10^5 and 2.0×10^6 ; and even more preferably, between 7.0×10^5 and 2.0×10^6 .

[0022] For the local administration of HA solution at the site of intended action to prevent platelet adhesion, the HA concentration can be from 0.1% to 5.0% with an HA solution viscosity that ranges from 20 centipoise to 300,000 centipoise.

[0023] Molecular weights of HA can be determined by light scattering measurements as described in Yu L.P. et al., "Rheological Characteristics of Microbially Derived Sodium Hyaluronate", American Chemical Society Proceedings Series - Harnessing Biotechnology for the 21 st Century, M.R. Ladisch and R. Bose eds., p 80-84, 1992.

[0024] Viscosity as described herein can be determined with a Brookfield cone and plate viscometer using the lowest shear rate that yielded results greater than 10% full scale.

[0025] As used herein, the term "HA" means hyaluronic acid and any of its hyaluronate salts, including, for example, sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, and calcium hyaluronate.

[0026] The term "platelet aggregation" as used herein means the amassing together of individual platelets through specific interactions between platelets.

[0027] The term "platelet adhesion" as used herein means the amassing of platelets onto a surface (e.g., a vascular wall, prosthetic device) through interactions of the platelets with the surface.

[0028] The terms "restenosis" and "reocclusion" as used herein mean the narrowing or constriction of the diameter of a vessel or duct.

[0029] The term "systemic" administration as used herein means to administer a substance at a substantial distance from the site where the substance is intended to act, usually by intravenous administration.

[0030] "Local administration", as used herein, refers to the contacting of a therapeutic agent, i.e., HA, in the immediate proximity of the tissue in the body where its therapeutic effect is desired.

[0031] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any method and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated by reference. Unless mentioned otherwise, the techniques employed or contemplated herein are standard methodologies well known to one of ordinary skill in the art. The materials, methods and examples are illustrative only and not intended to be limiting.

[0032] Our studies show that HA can be used to effect platelet adhesion and aggregation in a specific manner without interfering with other hemostatic events, unlike heparin and warfarin. For example, prior to the present invention, one common method of preventing vessel reocclusion following PTCA procedures is to place a stent device at the site of angioplasty in order to maintain the vessel patency and to administer heparin to reduce platelet adhesion to the stent. However, heparin has many effects on coagulation which are not always desirable in a vascular compromised state; heparin interferes with thromboxane production which is a potent regulator of normal platelet function, and heparin also has fibrinolytic activity which will induce lysis of clots in the general circulation.

[0033] In contrast, the methods of the invention may be practiced to decrease the risk of pathological thrombus formation associated with a diseased state or any medical procedure including cardiovascular surgery, cardiopulmonary bypass, catheterization (e.g., cardiac catheterization, or angioplasty) with a substantially reduced risk of affecting overall hemostasis. Further, HA will be especially useful in the cases where heparin and/or warfarin treatment may not be used, e.g., patients demonstrating protamine allergy, heparin induced thrombocytopenia, and warfarin resistance, as well those who are being treated with drugs which are incompatible with warfarin, or who are pregnant.

[0034] The drawings will first be briefly described.

Fig. 1 is a bar graph depicting the effect of HA infusion on arterial pressure.

Fig. 2 is a bar graph depicting the effect of HA infusion on cardiac output.

Fig. 3 is a bar graph depicting the effect of HA infusion on blood viscosity.

Fig. 4 is a bar graph depicting the effect of HA infusion on arterial O_2 .

Fig. 5 is a bar graph depicting the effect of HA infusion on bleeding time.

Fig. 6 is a graphic representation of the effect of HA infusion at 10% of blood volume on serum BUN values.

Fig. 7 is a graphic representation of the effect of HA infusion on Protein C levels.

Fig. 8 is a graphic representation of the effect of HA infusion on VWF levels.

Fig. 9 is a graphic representation of the effect of HA infusion on serum LDH.

Fig. 10 is a graphic representation of the effect of HA infusion on serum SGPT.

Fig. 11 is a graphic representation of the effect of HA infusion on serum SGOT.

Figs. 12A and 12B illustrate spectrometric measurement of the light transmittance of platelet samples treated with a PBS control (Fig. 12A) or 10% HA (Fig. 12B) in a ristocetin induced platelet aggregation assay.

Fig. 13 is a bar graph depicting the effects of HA and CMC on ristocetin induced platelet aggregation.

[0035] Hyaluronic acid (HA) is a component of the extracellular matrix in mammals that has been conserved throughout evolution. This mucopolysaccharide is a linear polymer built from repeating disaccharide units with the structure ... [D-glucuronic acid(1- β -3) N-acetyl-D-glucosamine (1- β -4)]_n. It is ubiquitous within the human body, and is found in a wide range of forms as a normal constituent in a variety of tissues including synovial fluid, vitreous humor, blood vessel

walls, pericardial fluid, and umbilical cord.

[0036] Hyaluronic acid is present in blood in low concentrations. It comes from the peripheral tissues via the lymph (Laurent et al., *Biochem. Int.* 2:195, 1981). From the concentration of hyaluronic acid in blood and its turnover rate as measured by labeled tracers, it has been estimated that a total amount of 10-100 mg turned over in the circulation of an adult human every day (Fraser et al., In *The Biology of Hyaluronan*, Ciba Foundation Symposium 143:41-59, Wiley, Chichester, England).

[0037] Dilute solutions of hyaluronic acid, in addition to being nonantigenic, are extremely lubricous, even at very low concentrations. HA solutions have been shown to reduce postoperative adhesion formation following abdominal (Urman et al., *Fertil Steril* 56:563, 1991) and orthopedic surgery (Hagberg et al., *J Hand Surg* 17A:935, 1992).

[0038] In addition to its anti-adhesion effects, HA solutions have been used clinically in ophthalmologic, orthopedic, and oral/maxillofacial surgery due to the unique viscoelastic properties of the material. Because of the high viscosity, administered HA solutions are retained in the anterior chamber of the eye and serve to protect fragile corneal endothelial surfaces during intraocular lens implantation (Pape et al., *Ophthalmology* 87:699, 1980). Injected into the joint space, HA solutions act as lubricants to provide pain relief in those with osteoarthritis (Iwata, *Clin Orthop* 289:285, 1993) and certain temporomandibular joint disorders (Bertolami et al., *J Oral Maxillofac Surg* 51:232, 1993). Interestingly, topical HA solutions have also been shown to be beneficial in the healing of tympanic membrane perforations (Hellstrom et al., *Acta Otolaryngol* 442:54, 1987).

[0039] The experiments described below describe the effect of HA on the function to inhibit platelet aggregation and adherence.

The Effect of HA on Bleeding Time

[0040] This study was designed to assess the effect of a large parenteral infusion of 0.4% HA in PBS (1.5×10^6 to 2.0×10^6 daltons), equivalent to either 2.5%, 5%, or 10% of the animal's measured blood volume. Hemodynamic, gas exchange, hematologic, and coagulation parameters were evaluated as described below. A separate infusion of PBS alone, equivalent to 10% of the blood volume in each animal, served as a control. Healthy male baboons (n=6) were used in this study, weighing between 27 and 36 kg (mean 30.2 kg).

[0041] *Experimental Protocol.* Approximately one week prior to study, each baboon's red cell volume was measured with ^{51}Cr labeled autologous red blood cells, and the plasma volume was measured using ^{125}I labeled albumin. Using this data, infusate volumes equivalent to 2.5%, 5%, and 10% of the circulating blood volume in each animal were determined. Each animal served as its own control and was thus studied on four occasions: once following infusion of PBS in a dose equal to 10% of the blood volume (control), and after infusions of test material doses equal to 2.5%, 5%, and 10% of the total blood volume. The order in which the control and test infusions were given was randomized. On the initial study day for each infusion, the animals were anesthetized with intramuscular ketamine (4 mg/kg), repeated as needed to maintain anesthesia. The right femoral artery was cannulated for mean arterial pressure measurement. A flow-directed pulmonary arterial thermodilution catheter was placed via the right internal jugular vein for measurement of central venous pressure, mean pulmonary arterial pressure, mean pulmonary artery wedge pressure, and cardiac output. After a steady state was achieved baseline samples were taken, followed by intravenous infusion of either the test or control material over a fifteen minute period. Sampling was done prior to infusion and 0.5, 1, 4, and 6 hours and 1, 2, 3, 7, 14, 21, and 28 days following infusion.

[0042] Hematocrit, hemoglobin, red blood cell count, white blood cell count, platelet count, and mean platelet volume were measured using an automated cell counter (Model JT, Coulter Corp., Hialeah, FL) for each time point as described above. Whole blood viscosity was measured using a porous bed viscometer (Crowley et al., *Am J Clin Pathol* 96:729, 1991). Blood pH, PO_2 , PCO_2 , sodium, potassium, ionized calcium, %O₂ hemoglobin, %CO hemoglobin, volume %O₂, and methemoglobin were measured using an automated blood gas analyzer (NovaStat Profile 4, Nova Biomedical, Waltham, MA). Mean arterial pressure, central venous pressure, mean pulmonary artery pressure, and mean pulmonary artery wedge pressure were measured by placement of a catheter into each of the femoral and pulmonary arteries. Bleeding time was measured by making a standard incision using a Simplate II bleeding time device (Organon Technika, Oklahoma City, OK). Core temperature was assessed in the pulmonary artery on the day of the study, and in the esophagus on the post-infusion days 1 through 28 using a pulmonary artery catheter placed in the esophagus. Skin temperature of the forearm was measured using a thermocouple (Mon-A-Therm) and an infra-red laser scanner (Exergen). Lung function was assessed by measuring respiration rate, and the pO_2 , pCO_2 and volume of expired air. Expired air was collected in Douglas bags and pO_2 and pCO_2 were measured using a Nova Stat Profile 4 instrument. Urine output was monitored throughout the study and urine samples were frozen for subsequent measurement of BUN

and creatinine. Red blood cell p50 was measured using a Hemoxanalyzer.

[0043] In addition, a portion of the blood samples obtained at each time point was frozen for later measurement of a number of criteria. Prothrombin time, partial thromboplastin time, thrombin time and fibrinogen were measured using an automated clotting machine (Coag-A-Mate, Organon Technika) (Feingold et al., *Am J Vet Res* 47:2197-2199, 1986).
 5 Antithrombin III (Helena Laboratories) was measured using a chromogenic assay (Abildgaard et al., *Thromb Res* 11: 549-553, 1977). Protein C was measured by a chromogenic assay supplied by America Bioproducts Co. (Nicham et al., *CBS* 65:25). von Willebrand's factor and D-dimer levels were measured using ELISA assays (supplied by American Bioproducts Co.; Ness et al., *Thromb Haemost* 42:848, 1979; Rylatt et al., *Thromb Res* 31:767, 1983). Fibronectin was measured using an immunoturbidimetric assay (supplied by Boehringer Mannheim Biochemicals; Saba et al., *J Lab*
 10 *Clin Med* 98:482, 1981). Serum and urea nitrogen (BUN) and creatinine, total protein, albumin, lactic dehydrogenase (LDH), alanine aminotransferase (SGPT), and aspartate aminotransferase (SGOT) were measured using an automated chemistry analyzer (Beckman Instruments Inc., Brea, CA). C3a and C5a dys Arg were measured using radioimmune assays (supplied by Amersham Corp.; Chenoweth et al., *N Engl J Med* 304:497, 1981). The thromboxane B2 level in the blood shed from the arm during the bleeding time measurement was determined by radioimmune assay (supplied
 15 by New England Nuclear Corp.). Red blood cell ATP and DPG were measured using a Farrand fluorometer (Lamprecht et al., In *Methods of Enzymatic Analysis*. HU Bergmeyer (ed), pp. 543-558, New York: Academic Press; Keitt, *Am J Med* 41:762-785, 1966).

[0044] *Statistical Analysis.* Data were examined using one-way analysis of variance (ANOVA) with repeated measures and Student-Newman-Keuls test. Statistical significance was achieved at $p < 0.05$. The results of the statistical
 20 analyses are displayed in tables 1-9.

[0045] 2.5% and 5% Groups. The infusion of 0.4% HA in PBS in volumes equivalent to 2.5% and 5% of the baboon's measured blood volume had no significant effect on any of the measured parameters compared to the control infusion.

[0046] 10% Group. Following infusion of a 0.4% HA solution in an amount equivalent to 10% of the circulating blood volume, there were no significant changes in central venous pressure, heart rate, or pulmonary arterial pressure. These
 25 animals did have a significant increase in mean arterial pressure in the first 30 minutes following infusion (+10% change), a finding not observed in the controls (Fig. 1). Cardiac output decreased significantly (-13% change) in the first hour, which returned to baseline within 4 hours (Fig. 2). There was a corresponding increase in blood viscosity (+52% change), systemic vascular resistance (+26% change) and pulmonary vascular resistance (+34% change), gradually returning to pre-infusion levels within 4-6 hours (Fig. 3). Arterial O₂ and venous pO₂ were significantly lower
 30 in the baboons infused with 10% HA/PBS (Fig. 4). The hematocrit, white cell count, and platelet count were not changed following infusion. However, the bleeding time significantly increased in the 10% group, to a level twice that of controls. This remained elevated for 72 hours post-infusion (Fig. 5).

[0047] Serum BUN and creatine values measured up to 48 hours following infusion were similar for baboons infused with PBS alone or 10% HA/PBS (Fig. 6). The prothrombin time, partial thromboplastin time, thrombin time, fibrinogen
 35 levels were not significantly changed. Protein C level and von Willebrand factor were significantly lower in the baboons infused with HA/PBS (Figs. 7 and 8). Red blood cell p50, red cell ATP, and red blood cell 2,3 DPG activities were unchanged in the animals treated with 10% HA/PBS when compared to controls. In addition, total protein, albumin, SGOT, SGPT, and LDH were unchanged by the 10% infusion (Figs. 9, 10, and 11).

[0048] HA is a normal constituent of serum and is rapidly catabolized within the intravascular space, with a half-life of only a few minutes (Laurent et al., *FASEB J* 6:2397, 1992). This may explain why infusion of the 0.4% HA solution equivalent to 2.5% or 5% of the circulating blood volume did not have a demonstrable effect on the various parameters measured. The clearance of HA can be described by Michaelis-Menton kinetics (Laurent et al., *supra*), and infusion of the 10% volume may briefly exceed the maximal metabolic rate (V_{max}), resulting in a transient increase in blood viscosity. Although whole blood viscosity is usually dependent on the prevailing hematocrit, changes in viscosity in the
 45 setting of a stable hematocrit (and arterial O₂ content) can cause independent changes in cardiac output and systemic vascular resistance (Murray et al., *Am J Physiol* 216:638, 1969). In addition, similar to whole blood, solutions containing HA act in a non-Newtonian fashion with viscosity being highly dependent on the shear rate (Laurent, *supra*). This could theoretically cause problems in the microcirculation, where the increased viscosity associated with low shear rates could induce stasis and sludging within vessels (Replogle et al., *Circulation* 36:148, 1967). However, evidence of this
 50 was not seen in this study, with at least indirect measurements of microcirculatory function (renal and liver function indices) remaining unchanged by the HA infusion.

EFFECTS OF TIME AND TREATMENT
AND INTERACTION BETWEEN TIME AND TREATMENT

1. Parameters measured up to 6 hours post-infusion Pre, 0.5, 1, 4, 6 (hours)

Hemodynamics, blood gases and pH, carbon monoxide, methemoglobin, electrolytes, saline transfused, and urine output

Analysis of variance
Volume Infused: 2.5%

<u>Parameters</u>	<u>Effect of time</u>	<u>Effect HA treatment</u>	<u>Interaction of HA (treatment) over time</u>
Heart Rate	.0348	NS	NS
MAP	NS	NS	NS
CVP	NS	NS	NS
MPA	.0292	NS	NS
MPAW	.0003	NS	NS
Cardiac Output			
Respiration			
Arterial pH	NS	NS	NS
" pCO ₂	.0149	NS	NS
" pO ₂	NS	NS	NS
Venous pH	NS	NS	NS
" pCO ₂	.0539	NS	NS
" pO ₂	.0213	NS	NS
Arterial O ₂ Saturation	NS	NS	NS
Venous O ₂ Saturation	.0003	NS	NS
Arterial O ₂ Content	.0021	NS	NS
Venous O ₂	.0003	NS	NS
Methemoglobin	NS	.0436*	NS
Carbon Monoxide	NS	NS	NS
Venous Na+			
Venous Cl-			
Saline Tx			
Urine Output	.0352	NS	NS

EP 1 262 200 A2

2. Parameters measured up to 72 hours post-infusion: Pre, 0.5, 1, 4, 6, 24, 48, 72 (hours)

Skin and core temperatures, bleeding time, viscosity, clotting, oncotic and opsonic proteins, p50, 2,3 DPG, ATP, and plasma hemoglobin.

	<u>Parameters</u>	<u>Effect of time</u>	<u>Effect HA treatment</u>	<u>Interaction of HA (treatment) over time</u>
	Skin temp	.0001	NS	NS
	Core temp	.0001	NS	NS
	Bleeding time	.0292	NS	NS
	Shed Blood TXB2			
	Viscosity	.0001	NS	NS
	PT			
	PTT			
	Thrombin Time			
	Fibrinogen			
	D-dimer			
	Anti-thrombin III			
	Protein C			
	von Willebrand's			
	Fibronectin			
	TP			
	Albumin			
	p50			
	2,3 DPG			
	ATP			
	Plasma hemoglobin			

3. Parameters measured up to 28 days post-infusion: Pre, 0.5, 1, 4, 6, 24, 48, 72, 168, 336, 504, 672 (hours).

	<u>Parameters</u>	<u>Effect of time</u>	<u>Effect HA treatment</u>	<u>Interaction of HA (treatment) over time</u>
	Serum BUN			
	Serum creatinine			
	Serum SGPT			
	Serum SGOT			
	Serum LDH			
	Hct	.0001	NS	NS
	Hb	.0001	NS	NS
	RBC	.0001	NS	NS
	WBC	.0001	NS	NS
	Platelet Count	.0001	NS	.0146
	Mean platelet volume	.0001	NS	NS

EFFECTS OF TIME AND TREATMENT
AND INTERACTION BETWEEN TIME AND TREATMENT

1. Parameters measured up to 6 hours post-infusion Pre, 0.5, 1, 4, 6 (hours)

Hemodynamics, blood gases and pH, carbon monoxide, methemoglobin, electrolytes, saline transfused, and urine output.

Analysis of variance
Volume Infused: 5%

<u>Parameters</u>	<u>Effect of time</u>	<u>Effect HA treatment</u>	<u>Interaction of HA (treatment) over time</u>
Heart Rate	.0371	NS	NS
MAP	.0111	NS	NS
CVP	.0053	NS	NS
MPA	NS	NS	NS
MPAW	.0030	NS	NS
Cardiac Output			
Respiration			
Arterial pH	NS	NS	NS
" pCO ₂	NS	NS	NS
" pO ₂	NS	NS	NS
Venous pH	NS	NS	NS
" pCO ₂	NS	NS	NS
" pO ₂	NS	NS	.0463
Arterial O ₂ Saturation	NS	NS	NS
Venous O ₂ Saturation	NS	NS	NS
Arterial O ₂ Content	.0029	NS	NS
Venous O ₂	.0105	NS	NS
Methemoglobin	NS	.0459*	NS
Carbon Monoxide	NS	NS	NS
Venous Na ⁺			
Venous Cl ⁻			
Saline Tx			
Urine Output	.0352	NS	NS

EP 1 262 200 A2

2. Parameters measured up to 72 hours post-infusion: Pre, 0.5, 1, 4, 6, 24, 48, 72 (hours)

5 Skin and core temperatures, bleeding time, viscosity, clotting, oncotic and opsonic proteins, p50, 2,3 DPG, ATP, and plasma hemoglobin.

	<u>Parameters</u>	<u>Effect of time</u>	<u>Effect HA treatment</u>	<u>Interaction of HA (treatment) over time</u>
10	Skin temp	.0001	NS	NS
	Core temp	.0006	NS	NS
	Bleeding time	.0181	NS	NS
	Shed Blood TXB2			
15	Viscosity	.0001	NS	NS
	PT			
	PTT			
	Thrombin Time			
	Fibrinogen			
	D-dimer			
20	Anti-thrombin III			
	Protein C			
	von Willebrand's			
	Fibronectin			
	TP			
	Albumin			
25	p50			
	2,3 DPG			
	ATP			
	Plasma hemoglobin			

30 3. Parameters measured up to 28 days post-infusion: Pre, 0.5, 1, 4, 6, 24, 48, 72, 168, 336, 504, 672 (hours).

Renal, liver and hematologic parameters.

	<u>Parameters</u>	<u>Effect of time</u>	<u>Effect HA treatment</u>	<u>Interaction of HA (treatment) over time</u>
35	Serum BUN			
	Serum creatinine			
40	Serum SGPT			
	Serum SGOT			
	Serum LDH			
	Hct	.0001	NS	NS
	Hb	.0001	NS	NS
45	RBC	.0001	NS	NS
	WBC	.0001	NS	NS
	Platelet Count	.0001	NS	NS
	Mean platelet	.0004	NS	NS

EFFECTS OF TIME AND TREATMENT
AND INTERACTION BETWEEN TIME AND TREATMENT

1. Parameters measured up to 6 hours post-infusion Pre, 0.5, 1, 4, 6 (hours)

Hemodynamics, blood gases and pH, carbon monoxide, methemoglobin, electrolytes, saline transfused, and urine output.

Analysis of variance
Volume Infused: 10%

<u>Parameters</u>	<u>Effect of time</u>	<u>Effect HA treatment</u>	<u>Interaction of HA (treatment) over time</u>
Heart Rate	0.0127*	0.5810	0.3410
MAP	0.0057*	0.7820	0.0029*
CVP	0.343	0.6490	0.1488
MPA	0.0677	0.3870	0.6271
MPAW	0.0041*	0.0260*	0.2721
Cardiac Output	0.8612	0.1295	0.0006*
Respiration	0.0072*	0.9395	0.1333
Arterial pH	0.8287	0.2338	0.9926
" pCO ₂	0.0257*	0.3454	0.7003
" pO ₂	0.4271	0.3423	0.7644
Venous pH	0.3598	0.7703	0.8216
" pCO ₂	0.0073*	0.5153	0.8591
" pO ₂	0.0114*	0.2904	0.0214*
Arterial O ₂ Saturation	0.0003*	0.1678	0.0050*
Venous O ₂ Saturation	0.0020*	0.2671	0.0135*
Arterial O ₂ Content	0.0032*	0.5343	0.4442
Venous O ₂	0.0001*	0.6279	0.1254
Methemoglobin	0.0001*	0.0317*	0.0001*
Carbon Monoxide	0.0060*	0.7206	0.2626
Venous Na ⁺	0.0044*	0.9120	0.3206
Venous Cl ⁻	0.2386	0.9302	0.9587
Saline Tx	0.0001*	0.1545	0.3500
Urine Output	0.0203*	0.7612	0.0473*

2. Parameters measured up to 72 hours post-infusion: Pre, 0.5, 1, 4, 6, 24, 48, 72 (hours)

5 Skin and core temperatures, bleeding time, viscosity, clotting, oncotic and opsonic proteins, p50, 2,3 DPG, ATP, and plasma hemoglobin.

10	<u>Parameters</u>	<u>Effect of time</u>	<u>Effect HA treatment</u>	<u>Interaction of HA (treatment) over time</u>
	Skin temp	0.0001*	0.8369	0.1373
	Core temp	0.2120	0.7787	0.8103
	Bleeding time	0.0003*	0.0062*	0.0001*
	Shed Blood TXB2	0.1601	0.5342	0.8583
15	Viscosity	0.0001*	0.0194*	0.0002*
	PT	0.0521	0.7337	0.2202
	PTT	0.0033*	0.7588	0.4737
	Thrombin Time	0.0001*	0.9433	0.5124
	Fibrinogen	0.0001*	0.4573	0.0673
	D-dimer	0.0005*	0.5221	0.1635
20	Anti-thrombin III	0.0004*	0.6052	0.1895
	Protein C	0.7756	0.7879	0.0084*
	von Willebrand's	0.0535	0.7926	0.0112*
	Fibronectin	0.0208*	0.3894	0.5720
	TP	0.0001*	0.0754	0.6677
25	Albumin	0.0899	0.3915	0.2630
	p50	0.0316*	0.1838	0.2080
	2,3 DPG	0.0019*	0.2292	0.1166
	ATP	0.1202	0.2661	0.0888
	Plasma hemoglobin	0.3590	0.7592	0.7843

30 3. Parameters measured up to 28 days post-infusion: Pre, 0.5, 1, 4, 6, 24, 48, 72, 168, 336, 504, 672 (hours).

Renal, liver and hematologic parameters.

35	<u>Parameters</u>	<u>Effect of time</u>	<u>Effect HA treatment</u>	<u>Interaction of HA (treatment) over time</u>
	Serum BUN	0.9810	0.9662	0.0011*
40	Serum creatinine	0.1927	0.8304	0.1944
	Serum SGPT	0.0001*	0.5060	0.8706
	Serum SGOT	0.0001*	0.8115	0.8173
	Serum LDH	0.0001*	0.7189	0.5675
	Hct	0.0001*	0.0974	0.7221
	Hb	0.0001*	0.0351*	0.9951
45	RBC	0.0001*	0.6320	0.5396
	WBC	0.0001*	0.8738	0.8379
	Platelet Count	0.0001*	0.0240*	0.2245
	Mean platelet volume	0.0001*	0.7362	0.1315

The Role of HA in Platelet Interaction

55 [0049] For adhesion to occur, the platelet must contact the vessel wall and then spread onto components of the subendothelial matrix. The platelet surface membrane has adhesion receptors that bind to specific matrix molecules. These receptors include the glycoprotein (gp)Ib-IX complex, a receptor for subendothelial von Willebrand factor, and several of the membrane glycoproteins of the integrin superfamily of adhesion receptors: gplα/IIa (a collagen receptor),

gpIc/IIa (a fibronectin receptor), gpIc/IIa (a laminin receptor), and $\alpha_v\beta_3$ (a vitronectin receptor). In addition, many components of the matrix, such as von Willebrand factor, thrombospondin, fibronectin, and collagen, can interact with one another as well as with platelets. Once activation has occurred, another platelet-membrane integrin, gpIIb/IIIa, becomes competent to bind von Willebrand factor and fibronectin and is involved in the spreading of platelets on the subendothelial matrix.

[0050] Ristocetin is an agent which specifically promotes platelet aggregation by inducing the monophasic agglutination reaction of vWF binding to the glycoprotein 1b receptor on platelets. After vWF binds to gpIb, the platelets release ADP and serotonin, both which are effective platelet aggregating agents. Thus, we investigated the effect of HA on platelet aggregation mediated by von Willebrand factor binding to the platelet gpIb receptor in the following experiment.

[0051] Platelet aggregation was performed using a Series 1000B Payton Scientific Lumi-Aggregometer as follows. Platelet-rich-plasma (PRP) was prepared from fresh whole blood anticoagulated with sodium citrate by centrifuging it for 10 minutes at 200 x g and removing the upper PRP layer. The PRP was adjusted to 300,00/ μ l with platelet-poor-plasma (prepared by centrifuging the blood a second time at 100 x g for 10 minutes). To 400 μ l of PRP was added 50 μ l of 0.4%w/w HA solution (molecular weight 2.2×10^6 , 10% final concentration) or, PBS carrier buffer. After a 5 minute incubation at 37°C, 50 μ l of 12 mg/mL ristocetin (Bio/Data Corp) were added to induce the aggregation reaction (mediated by platelet gpIb receptor and plasma vWF). Changes in sample light transmittance was monitored for 5 minutes after addition of ristocetin. Initial rate is the maximum slope of agglutination obtained during the first minute.

[0052] The slope of the agglutination reaction and the biphasic shape of the aggregation curve (Figure 12) shows that HA inhibited platelet aggregation induced by the vWF and platelet gpIb receptor interaction.

[0053] A second experiment was performed to determine if the inhibition of vWF-gpIb induced platelet aggregation was specific for HA. We therefore compared HA to another polyanionic polysaccharide, carboxymethylcellulose (CMC). Two CMC solutions were tested in this study. Solution CMC-1 was 0.7% CMC (lot 7H3SF) at apparent viscosity = 350 centipoise (2.2 sec^{-1}). Solution CMC-2 was 2% CMC (7MFPH) at apparent viscosity = 350 centipoise (2.2 sec^{-1}). The CMC solutions were prepared to approximately the same viscosity as the HA solution and compared for ristocetin aggregation as described in the above example. The amount of platelet aggregation induced by ristocetin was significantly less with HA treatment as compared to CMC (Figure 13) indicating that the effect of HA on platelet aggregation is not related to the general viscosity of the polyanionic solution but is specific for HA.

[0054] Previous studies have reported that pigs with von Willebrand disease which were subjected to coronary vessel stenosis by an external ring did not develop vascular occlusion in contrast with normal animals (Nichols et al., *Circ. Res.* 59:15, 1986; Badimon et al. (*Circulation* 78:1431, 1998) further reported that the absence of vWF in both heparinized and nonanticoagulated blood significantly reduces platelet thrombus formation at high local wall shear rates (stenotic or microcirculatory flow), and also demonstrated a considerably greater reduction in platelet deposition compared with anticoagulation with heparin. They concluded that it is likely that vWF plays a significant role in the thrombotic complications associated with stenotic cardiovascular disease and that the acute thrombotic response may be more sensitive to manipulation of vWF than of other factors.

[0055] Accordingly, our demonstration that HA specifically interferes with the function of vWF establishes the therapeutic importance of HA in treating thrombotic conditions which are, or are at risk of becoming, life threatening.

USE

[0056] Compositions for administration according to the invention comprise a solution of HA dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g. water, buffered 0.9% saline and the like. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

[0057] Administration may be either by intermittent injections, for example, into an indwelling intravenous cannula or by pump-driven infusion at a constant rate. The exact effective dosage varies with the patient's weight and may be influenced by a number of factors, including the route of administration, type and state of disease, and overall health status of the particular patient.

[0058] More specifically, HA can be used to prevent platelet adhesion and subsequent aggregation to a damaged vessel wall caused by any of the medical conditions mentioned herein. This can be accomplished, for example, by infusing a 0.4% HA solution, preferably in a physiological buffer, into the circulation remote from the endothelial damage, through a standard means such as by an intravenous or intraarterial catheter. The HA solution would be administered in an amount greater than 5% of the patient's blood volume, or preferably 10% of the patient's blood volume.

[0059] Alternatively, the HA could be administered directly to the site of endothelial damage. One method by which this can be accomplished is by placing a catheter directly at the site of endothelial cell damage and slowly administering

the HA proximal to the site of damage. In this case an effective dose of HA solution would be less than that required when administering the solution remote from the site of endothelial cell damage.

[0060] A specific example of the latter is the prevention of platelet adhesion to damaged endothelium caused by percutaneous transluminal coronary angioplasty (PTCA). In this procedure a balloon catheter is placed into a coronary artery that is partially occluded. The balloon is inflated to expand the inner diameter of the artery, thus improving blood flow through the vessel. This procedure often damages the endothelium of the artery which leads to undesired deposition of circulating blood cells on the damaged vessel wall. Cells which adhere to the vessel wall include platelets, white blood cells, and granulocytes. Following inflation of the balloon and prior to removing the catheter, HA solution of 0.1% to 5% is infused through the catheter just proximal from the site of angioplasty in order to interfere with platelet or granulocyte adherence to the damaged vessel wall. By reducing the adherence of these cells to the vessel wall the vessel patency is maintained and vessel reocclusion is reduced or prevented.

[0061] The use of HA solution in this way can be also applied following arteriotomy, which also damages the vessel wall and thus causes platelet deposition, thrombosis, and reocclusion.

[0062] HA can also be used to prevent or reduce platelet adhesion to vascular prostheses such as collagen or synthetic vascular grafts, natural or synthetic heart valves, vascular stents, and other blood contacting products and materials such as blood dialysis membranes, catheters, tubing, etc. Prevention of platelet adherence to these substrates is accomplished by coating HA, or its derivatives, to the surface of the prosthetic or blood contacting material which will be in contact with the blood using standard techniques. Upon exposure to blood, platelets will be less likely to adhere to the surface compared to non-HA coated surfaces. The efficacy of any device may be tested prior to use by standard cell adhesion assays well known to those skilled in the art. For example, a small sample containing a platelet suspension is incubated with a concentration of HA or device coated with HA at physiological temperature, and then, for example, by placing the sample in a Neubauer chamber and evaluating the percentage of platelets found in aggregates of two or more by light microscopy (or alternatively by percentage of platelets bound to the surface of the device to be examined).

[0063] From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. For example, homologues, analogues, derivatives and complexes of HA which are capable of inhibiting the action of vWF may also be used in the methods of the invention (e.g., Balasz, U.S. Patent No. 4,582,865; De Belder PCT Publication No. WO 86/00912; Malson et al., PCT Publication No. 84/20560; Prestwich et al., EP Publication No. 0416250A2; Hamilton et al., U.S. Patent No. 4,937,270; and Burns et al., U.S. Patent No. 5,017,229); any particular compound of HA may be tested for efficacy according to the methods described herein.

[0064] In addition, the invention also includes the use of HA and its chemically modified derivatives to deliver therapeutic drugs directly to sites where platelets have already adhered. For example drugs can be incorporated into the HA by admixing or by immobilizing the drug by chemical attachment to the HA molecule or by ionic interaction between the drug and HA (e.g., see Sparer et al., 1983, Chapter 6, pp. 107-119, In *Controlled Release Delivery Systems*, Roseman et al. (ed), Marcel Dekker, Inc.: New York). The HA-drug complex, or HA derivative complex can then bind to the vWF and deliver the drug in a site specific manner to the platelet or to the damaged vessel wall. A specific example is to mix the tissue plasminogen activator (tPA) with HA in a therapeutic dose and to infuse the HA as described in the above example. The HA will target the tPA directly to the platelets in blood clots and thereby deliver the drug site specifically where it must act.

Claims

1. A prosthetic device **characterised in that** it is coated with hyaluronic acid in an amount sufficient to inhibit the interaction of platelets with the said device.
2. A device as claimed in claim 1 wherein the said prosthetic device is synthetic or bioprosthetic, particularly a coronary valve, a stent or a vascular graft.




FIG. 1





FIG. 2

FIG. 3






FIG. 4




FIG. 5

FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12A






FIG. 12B







(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
12.03.2003 Bulletin 2003/11

(51) Int Cl.7: **A61L 31/10, A61L 27/34**

(43) Date of publication A2:
04.12.2002 Bulletin 2002/49

(21) Application number: **02077105.1**

(22) Date of filing: **01.06.1995**

(84) Designated Contracting States:
DE ES FR GB IT NL SE

(30) Priority: **07.06.1994 US 255252**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
95303739.7 / 0 686 395

(71) Applicants:
• **GENZYME CORPORATION**
Cambridge, Massachusetts 02139 (US)
• **The Trustees of Boston University**
Boston, MA 02215 (US)

(72) Inventors:

- **Burns, James W.**
Watertown, MA 02472 (US)
- **Valeri, Cesare R.**
Marblehead, Massachusetts 01945 (US)

(74) Representative: **Froud, Clive et al**
Elkington and Fife
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR (GB)

(54) **Inhibition of platelet adherence and aggregation**

(57) A prosthetic device characterised in that it is coated with hyaluronic acid in an amount sufficient to inhibit the interaction of platelets with the said device is disclosed.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 07 7105

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
P,X	WO 94 24961 A (SCHNEIDER USA INC) 10 November 1994 (1994-11-10) * claims 13,21,24 *	1,2	A61L31/10 A61L27/34
X	WO 88 02623 A (BIO METRIC SYSTEMS INC) 21 April 1988 (1988-04-21) * page 8, paragraph 2 *	1,2	
X	US 4 500 676 A (BALAZS ENDRE A ET AL) 19 February 1985 (1985-02-19) *abstract* * column 1, line 20 - line 34 * * claim 5 *	1,2	
X	US 5 023 114 A (HALPERN GREGORY ET AL) 11 June 1991 (1991-06-11) * column 2, line 64 - column 3, line 7 * * column 3, line 42 - line 50 * * claim 2 *	1,2	
X	US 5 132 108 A (NARAYANAN PALLASSANA V ET AL) 21 July 1992 (1992-07-21) * column 1, line 7 - line 21 * * column 4, line 60 - column 5, line 5 * * example 11 *	1,2	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K A61L
A	WO 89 11857 A (UNIV FLORIDA) 14 December 1989 (1989-12-14) * claims 1-17 *	1,2	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 8 January 2003	Examiner Schnack, A
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons * : member of the same patent family, corresponding document	

EPC FORM 1503 03 92 (P04.001)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 07 7105

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-01-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9424961	A	10-11-1994	CA 2158757 A1	10-11-1994
			EP 0695152 A1	07-02-1996
			JP 2735389 B2	02-04-1998
			JP 8504650 T	21-05-1996
			WO 9424961 A1	10-11-1994
WO 8802623	A	21-04-1988	AT 116863 T	15-01-1995
			AU 615637 B2	10-10-1991
			AU 8232087 A	06-05-1988
			CA 1305068 A1	14-07-1992
			DE 3750989 D1	23-02-1995
			DE 3750989 T2	18-05-1995
			EP 0326579 A1	09-08-1989
			JP 2981488 B2	22-11-1999
			JP 10179726 A	07-07-1998
			JP 2500250 T	01-02-1990
			JP 2741378 B2	15-04-1998
			WO 8802623 A1	21-04-1988
			US 4973493 A	27-11-1990
			US 5512329 A	30-04-1996
			US 4979959 A	25-12-1990
			US 5002582 A	26-03-1991
			US 5741551 A	21-04-1998
			US 5217492 A	08-06-1993
			US 5263992 A	23-11-1993
US 4500676	A	19-02-1985	AU 551728 B2	08-05-1986
			AU 3209184 A	20-06-1985
			CA 1218776 A1	03-03-1987
			DE 3434042 A1	29-08-1985
			FR 2556733 A1	21-06-1985
			GB 2151246 A ,B	17-07-1985
			IT 1178586 B	09-09-1987
			JP 60130623 A	12-07-1985
US 5023114	A	11-06-1991	US 4801475 A	31-01-1989
			DE 3529758 A1	27-02-1986
			FR 2569374 A1	28-02-1986
			FR 2649404 A1	11-01-1991
			GB 2163436 A ,B	26-02-1986
			IL 75729 A	19-03-1990
			US 4959074 A	25-09-1990
			US 5037677 A	06-08-1991
US 5132108	A	21-07-1992	NL 9201301 A	16-02-1994
			US 5486357 A	23-01-1996

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 07 7105

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-01-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 5132108	A	US 5409696 A	25-04-1995	
		US 5591140 A	07-01-1997	
		US 5244654 A	14-09-1993	

WO 8911857	A	14-12-1989	AT 117898 T	15-02-1995
			DE 68921002 D1	16-03-1995
			DE 68921002 T2	08-06-1995
			EP 0420877 A1	10-04-1991
			JP 6077601 B	05-10-1994
			JP 3504602 T	09-10-1991
			US 5350573 A	27-09-1994
			WO 8911857 A1	14-12-1989
			US 6010692 A	04-01-2000
			US 6464970 B1	15-10-2002
			US 5632979 A	27-05-1997
			US 5080893 A	14-01-1992
			US 5140016 A	18-08-1992
			US 6086907 A	11-07-2000

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82